Psychiatry 2008 - September 2008 - (Page 50)

[research to practice] 3. 4. 5. 6. 7. 8. 9. 10. Rapid oral loading of extended release divalproex in patients with acute mania. Gen Hos Psychiatry. 2005;27(3):218–221. Feifel D. Dosing of divalproex extended release. J Clin Psychiatry. 2007;68(7):1146–1147; author reply 1147. Feifel D. When common clinical practice meets evidence-based medicine. Psychiatry (Edgemont). 2006;3(12):36–38. Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biologic Psychiatry. 2007;62(11):1217–1227. Thase ME. Are SNRIs more effective than SSRIs? a review of the current state of the controversy. Psychopharmacol Bull. 2008;41(2):58–85. Anderson IM. SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety. 1998;7(Suppl 1):11–17. Tzanakaki M, Guazzelli M, Nimatoudis I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol. 2000;15(1):29–34. Clerc GE, Ruimy P, Verdeau-Pallès J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol. 1994;9(3):139–143. Benkert O, Gründer G, Wetzel H, et al. A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. in inpatients with major depression and melancholia. J Psychiatr Res. 1996;30(6):441–451. Wirz-Justice A, Benedetti F, Berger M, et al. Chronotherapeutics (light and wake therapy) in affective disorders. Psychologic Med. 2005;35(7):939–944 Neumeister A, Goessler R, Lucht M, et al. Bright light therapy stabilizes the antidepressant effect of partial sleep deprivation. Biologic Psychiatry. 1996;39(1):16–21. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and metaanalysis of the evidence. Am J Psychiatry. 2005;162(4):656–662. Caliyurt O, Guducu F. Partial sleep deprivation therapy combined with sertraline induces more rapid improvements in quality of life items in major depressive disorder. J Affec Dis. 2005;88(1):75–78. Martiny K. Adjunctive bright light in non-seasonal major depression. Acta Psychiatr Scand. 2004;110:7–28. Benedetti F, Colombo C, Pontiggia A, et al. Morning light treatment hastens the antidepressant effect of citalopram: a placebo-controlled trial. J Clin Psychiatry. 2003;64(6):648–653. Even C, Schröder CM, Friedman S, et al. Efficacy of light therapy in nonseasonal depression: a systematic review. J Affect Dis. 2008;108(1–2):11–23 Mishima K, Okawa M, Hishikawa Y, et al. Morning bright light therapy for sleep and behavior disorders in elderly patients with dementia. Acta Psychiatric Scand. 1994;89(1):1–7. Loving RT, Kripke DF, Shuchter SR. Bright light augments antidepressant effects of medication and wake therapy. Depress Anxiety. 2002;16(1):1–3. Güdücü F, Caliyurt O, Vardar E, et al. [Combination therapy using sertraline with sleep deprivation and 21. 22. light therapy compared to sertraline monotherapy for major depressive disorder]. Turk Psikiyatri Dergisi. 2005;16(4):245–251. Caliyurt O, Guducu F. Partial sleep deprivation therapy combined with sertraline induces more rapid improvements in quality of life items in major depressive disorder. J Affect Dis. 2005;88(1):75–78. Zarate CA, Singh JB, Carlson PJ, et al. A randomized trial of an Nmethyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864. AUTHOR AFFILIATION: Dr. Feifel is Professor, Department of Psychiatry; Director, Neuropsychiatry and Behavioral Medicine Program; Director, UCSD Adult ADHD Program, University of California, San Diego Medical Center, San Diego, California. DISCLOSURES: Dr. Feifel has received research funding, consulting, or speaking fees from the following pharmaceutical companies: Abbott Laboratories, AstraZeneca, Argolyn Biosciences, Eli Lilly and Co., Bristol-Myers Squibb, Solvay, Janssen, Wyeth, McNeil, and Shire. ADDRESS CORRESPONDENCE TO: David Feifel, MD, PhD, Department of Psychiatry, University of California, San Diego Medical Center, 200 West Arbor Drive, San Diego, CA 92103-8218; E-mail: dfeifel@ucsd.edu 50 Psychiatry 2008 [S E P T E M B E R ]

Table of Contents Feed for the Digital Edition of Psychiatry 2008 - September 2008

Psychiatry 2008 - September 2008 Editor’s Message Editorial Advisory Board Contents Psych Rx Letters to the Editor Use of Benzodiazepines in the Treatment of Anxiety Functional Neurosurgery in the Treatment of Severe Obsessive Compulsive Disorder and Major Depression: Overview of Disease Circuits and Therapeutic Targeting for the Clinician Treatment of Comorbid Adolescent Cannabis Use and Major Depressive Disorder Risperidone Long-acting Injections: Successful Alternative Deltoid Muscle Injections for Refractory Schizophrenia Alcohol/Substance Misuse and Treatment Nonadherence: Fatal Attraction Transforming the Psychiatric Inpatient Unit from Short-term Pseudo-asylum Care to State-of-the-art Treatment Setting Journal Watch Classified Advertising Information for Authors

Psychiatry 2008 - September 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.